Problem Solved by the Technology
Most current cancer treatments are delivered systemically,and are usually associated with undesirable side-effects, including nausea, hair loss, and weakness.
Dr. Minsoo Kim at the University of Rochester has engineered the means to direct ex vivo-generated immune-promoting or tolerogenic T cells either to enhance immunity or to promote adoptive cell transfer therapies in patients. By applying this methodology to tumor-targeting cytotoxic T cells, Dr. Kim has been able to achieve a significant reduction in tumor growth in mouse models. Clinically, this photoactivatable chemokine receptor approach may have broad applications for adoptive cell transfer therapy.
Xu Y et al. Optogenetic Control of Chemokine Receptor Signal and T-cell Migration. PNAS. 2014 Apr 29; 111(17):6371-6.
Intellectual Property Status
Patent applications pending in United States, Australia, Canada, and Europe.
URV Reference Number: 6-1995